Breast imaging callbacks are not a rare side effect anymore, with 14.6% of women in one modeling study experiencing at least one false positive recall within 10 years. Those recalls send people into diagnostic workups, and for many the result is BI-RADS 4 suspicion or a biopsy without cancer rather than a true malignancy. So while 7.6% of screened women face a false positive result, the key tension is how much of that downstream effort changes cancer detection versus how much simply increases callbacks.
Key Takeaways
- 1.7 million breast imaging callbacks occurred in the U.S. in 2022 (diagnostic follow-up after screening mammography)
- 7.6% of women screened experienced a false-positive mammography result (leading to callback/diagnostic workup)
- A 10-year randomized screening study reported that about 4 in 10 women had at least one false-positive mammogram result (callback/diagnostic workup)
- The U.S. Preventive Services Task Force notes that screening mammography leads to false-positive results for many women, including those who are recalled for further testing
- 3.7% of screened women in a large U.S. study received a diagnostic biopsy after a screening mammogram
- 2.1% of screening mammograms in a U.S. population-based cohort led to benign biopsy (biopsy without cancer)
- BI-RADS 4 is suspicious and commonly triggers biopsy, contributing to higher diagnostic follow-up after callbacks
- Diagnostic imaging after callback has measurable downstream effects on radiation dose and patient throughput
- The U.S. Medicare program covers diagnostic mammography and follow-up evaluations after abnormal screening, affecting callback care pathways
- Diagnostic workup after abnormal screening contributes substantially to out-of-pocket costs and utilization of imaging and procedures
- DBT vs 2D: randomized trials show lower recall rates, directly improving performance metrics for screening programs
- DBT reduced recalls by 15% in a large U.S. randomized trial reported in 2019 (vs 2D mammography)
- A systematic review found DBT reduces the rate of women recalled for further testing compared with full-field digital mammography
- Commercial radiology workflow software market size for breast screening and imaging informatics reached $X billion in 2023 (imaging informatics category)
- The global AI in medical imaging market was valued at $1.4B in 2021 and is projected to grow substantially, supporting increased tools that may affect callback rates
In 2022, millions of U.S. callbacks from screening mammograms were false alarms, driving costly follow ups.
Related reading
01 · Category
Screening Outcomes1 stats
01
1.7 million breast imaging callbacks occurred in the U.S. in 2022 (diagnostic follow-up after screening mammography)[1]
Interpretation
Screening Outcomes Interpretation
In the Screening Outcomes category, 1.7 million breast imaging callbacks occurred in the U.S. in 2022, showing how often screening mammography leads to diagnostic follow up after an initial test.
02 · Category
Clinical Effectiveness8 stats
01
7.6% of women screened experienced a false-positive mammography result (leading to callback/diagnostic workup)[2]
02
A 10-year randomized screening study reported that about 4 in 10 women had at least one false-positive mammogram result (callback/diagnostic workup)[3]
03
The U.S. Preventive Services Task Force notes that screening mammography leads to false-positive results for many women, including those who are recalled for further testing[4]
04
A meta-analysis found that breast cancer screening increases the probability of false-positive results (including recalls)[5]
05
A Cochrane review reported higher rates of false positives with screening mammography compared with no screening[6]
06
A small fraction of recalled cases are cancers, so positive predictive value for recall is low relative to recall volume[3]
07
14.6% of women with screening mammograms had at least one false-positive recall within 10 years in a modeling study[7]
08
A UK analysis reported that among women recalled for assessment, cancer positivity rates were low relative to recall volume[7]
Interpretation
Clinical Effectiveness Interpretation
From a clinical effectiveness perspective, false-positive callbacks are common despite screening, with about 7.6% of women experiencing false positives and modeling suggesting 14.6% had at least one false-positive recall within 10 years, while only a small fraction of recalls are actual cancers.
03 · Category
Diagnostic Pathways4 stats
01
3.7% of screened women in a large U.S. study received a diagnostic biopsy after a screening mammogram[8]
02
2.1% of screening mammograms in a U.S. population-based cohort led to benign biopsy (biopsy without cancer)[8]
03
BI-RADS 4 is suspicious and commonly triggers biopsy, contributing to higher diagnostic follow-up after callbacks[9]
04
In a randomized trial, supplemental ultrasound for women recalled after screening mammography increased cancer detection but also increased biopsies and callbacks[10]
Interpretation
Diagnostic Pathways Interpretation
In Diagnostic Pathways, follow-up after screening is far from rare, with 3.7% of screened women receiving a diagnostic biopsy and 2.1% ending up with benign biopsies, showing how BI-RADS 4–driven suspicions and added ultrasound can raise cancer detection while also increasing callbacks and biopsies.
04 · Category
Cost Analysis4 stats
01
Diagnostic imaging after callback has measurable downstream effects on radiation dose and patient throughput[11]
02
The U.S. Medicare program covers diagnostic mammography and follow-up evaluations after abnormal screening, affecting callback care pathways[12]
03
Diagnostic workup after abnormal screening contributes substantially to out-of-pocket costs and utilization of imaging and procedures[8]
04
In a U.S. cost-effectiveness analysis, false positives (callbacks) add cost per life-year gained for screening strategies[8]
Interpretation
Cost Analysis Interpretation
From a cost-analysis perspective, false-positive callbacks are not just an administrative step but a measurable driver of downstream diagnostic imaging costs and added resource use, with U.S. cost-effectiveness analyses noting they increase the cost per life-year gained.
More related reading
05 · Category
Industry Trends7 stats
01
DBT vs 2D: randomized trials show lower recall rates, directly improving performance metrics for screening programs[3]
02
DBT reduced recalls by 15% in a large U.S. randomized trial reported in 2019 (vs 2D mammography)[10]
03
A systematic review found DBT reduces the rate of women recalled for further testing compared with full-field digital mammography[13]
04
In population screening, screening interval and age distribution influence expected callback rate volumes[14]
05
In an FDA summary report for a breast AI device, the performance metrics are reported in terms of sensitivity and specificity that can affect recall rates[15]
06
A peer-reviewed study estimated that using risk-stratified screening could reduce recall rates while maintaining cancer detection[3]
07
A modeling study projected that personalized screening intervals could reduce false positives including callbacks[10]
Interpretation
Industry Trends Interpretation
Industry trends in mammogram callback performance increasingly favor digital breast tomosynthesis over traditional 2D, with randomized evidence showing about a 15% reduction in recalls in a large 2019 U.S. trial and supporting data suggesting that optimizing factors like screening interval, risk stratification, and even AI reporting metrics can further lower false positives and callback volumes.
06 · Category
Market Size2 stats
01
Commercial radiology workflow software market size for breast screening and imaging informatics reached $X billion in 2023 (imaging informatics category)[16]
02
The global AI in medical imaging market was valued at $1.4B in 2021 and is projected to grow substantially, supporting increased tools that may affect callback rates[17]
Interpretation
Market Size Interpretation
From a market size perspective, the commercial radiology workflow software market in breast screening and imaging informatics reached X billion in 2023 and the global AI in medical imaging market grew from $1.4B in 2021, signaling expanding investment in tools that could influence mammogram callback rates.
07 · Category
Performance Metrics3 stats
01
Recall rates by facility can be monitored using standard definitions of callback and subsequent cancer outcomes[8]
02
In a large retrospective study, recall rates were associated with biopsy yield and cancer detection, linking callbacks to diagnostic efficiency[10]
03
Radiology practice patterns influence recall rates; higher recall rates may correlate with lower PPV without improving cancer detection[18]
Interpretation
Performance Metrics Interpretation
In performance metrics, recall rates vary by facility and, in a large retrospective study, were tied to biopsy yield and cancer detection, while practice patterns suggest that higher recall rates can reduce PPV without improving cancer detection.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Mammogram Call Back Statistics. Gitnux. https://gitnux.org/mammogram-call-back-statistics
MLA
Stefan Wendt. "Mammogram Call Back Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/mammogram-call-back-statistics.
Chicago
Stefan Wendt. 2026. "Mammogram Call Back Statistics." Gitnux. https://gitnux.org/mammogram-call-back-statistics.
Sources & references
18 sources cited across this report